OncoCyte Corp (OCX) Downgraded by ValuEngine

ValuEngine cut shares of OncoCyte Corp (NYSEMKT:OCX) from a hold rating to a sell rating in a report published on Thursday.

OncoCyte Corp (OCX) opened at 5.95 on Thursday. The firm’s 50-day moving average price is $6.54 and its 200-day moving average price is $6.54. OncoCyte Corp has a 52-week low of $3.75 and a 52-week high of $7.95. The company’s market cap is $186.45 million.

TRADEMARK VIOLATION NOTICE: This report was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/10/08/oncocyte-corp-ocx-downgraded-by-valuengine.html.

About OncoCyte Corp

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply